"In our experience, the European patent licensing landscape does not actually exist. Over recent years, each industry has developed – rarely by formal processes, but simply by practice – its own licensing principles and standards." Read more
The agency's outgoing head Francis Gurry has hit out at media coverage of complaints made against him by his deputy, but the real problem was a total lack of transparency in how the affair was handled Read more
Samsung on the hook for over $135 million this year alone, with China's national IP office and the USPTO set to pull in $100 billion over lifetime of all their active grants Read more
This chapter aims to give a brief overview of the patent litigation system in Switzerland and highlight some current trends in life sciences patent litigation. Read more
Päivi Kairamo, chair of WIPO’s General Assemblies, has asked the United Nations’ Organisation of Internal Oversight Services (OIOS) to investigate the claims made by James Pooley, the former deputy director general of the organisation, in a Report…
With intellectual property under more scrutiny than it has ever been before, problems at three of the world’s top IP agencies could not have occurred at a worse time. The major controversies besetting both the European Patent Office and the World…
Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more
This blog was updated on 12th October to include new information about the vote that took place in Geneva on 7th October and to provide links to further documents that have been made public, including what is said to be an unredacted copy of the…
This blog has been updated to include additional material relating to the report compiled by the UN's Office of Internal Oversight Services following its investigation into alleged misconduct by WIPO DG Francis Gurry.
In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
Court developments In Switzerland, the Federal Patent Court is exclusively competent for patent infringement and validity cases. The number of cases handled by the court has remained relatively constant over the past three years. In its annual… Read more
A recent Federal Patent Court decision considered the applicability of international patent exhaustion due to the subordinate significance of the patented features. It confirms that the requirements to avoid international patent exhaustion appear to be rather high, in particular with respect to complex products where most of the patent rights concern not the whole product, but rather only some component thereof.
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
This blog has been updated to include additional material relating to the report compiled by the UN's Office of Internal Oversight Services following its investigation into alleged misconduct by WIPO DG Francis Gurry.
Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more
In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
New research finds that Europe is ahead of the rest when it comes to the quality of innovations and also leads in filing international patents Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
The research centres which produce the most world-leading assets are currently found in the US and Europe, but analysis shows that Chinese universities are beginning to catch up(Picture: MIT) Read more
While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries.
Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
The research centres which produce the most world-leading assets are currently found in the US and Europe, but analysis shows that Chinese universities are beginning to catch up(Picture: MIT) Read more
While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries.
Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
With intellectual property under more scrutiny than it has ever been before, problems at three of the world’s top IP agencies could not have occurred at a worse time. The major controversies besetting both the European Patent Office and the World…
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
